PTC Therapeutics, a US pharmaceutical company, completed the acquisition of Censa Pharmaceuticals, a biopharmaceutical company, for $41m. The deal also includes $217m more tied to development and regulatory milestones for Censa’s two most advanced programs plus a priority review voucher, which allows for expedited FDA review. "We're thrilled to complete the acquisition of Censa. This acquisition adds a well-established late-stage PKU clinical program to our growing rare disease portfolio. Given PTC's established development and commercial capabilities, we're well-positioned to bring this therapy to patients with unmet medical need expeditiously," Stuart W. Peltz, PTC Therapeutics CEO.